The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss
Launched by CHANG GUNG MEMORIAL HOSPITAL · May 30, 2022
Trial Information
Current as of November 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a medication called topiramate can help treat sudden sensorineural hearing loss (SSNHL) when used alongside steroids. SSNHL is a condition that can lead to sudden deafness. While steroids are commonly used to treat this condition, researchers want to see if adding topiramate, which is often used to prevent migraines, can improve outcomes even more. The study will involve patients who have been diagnosed with SSNHL within the last 14 days and will take place in several hospitals across Taiwan.
To participate in this trial, patients must be over 20 years old and have a confirmed diagnosis of SSNHL. Patients with certain other ear conditions, previous treatments, or serious health issues may not be eligible. Those who agree to join the study will be randomly placed into two groups: one will receive steroids alone, while the other will get steroids plus topiramate for six weeks. All participants will be followed for at least three months to see how well the treatment works. This research aims to find out if combining these treatments can provide better results for those experiencing sudden hearing loss.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 20
- • Confirmed diagnosis of unilateral sudden sensorineural hearing loss(SSNHL)
- • Treatment started 14 days within onset of SSNHL
- Exclusion Criteria:
- • Previous SSNHL history
- • Previous middle ear disorder such as chronic otitis media, or previous ear surgery
- • Meniere's disease and fluctuating hearing loss patients
- • Pregnancy or trying to become pregnant
- • Leukemia, hemodialysis, and patients who received chemotherapy before.
- • Previous head and neck radiotherapy
- • cerebellopontine angle tumors such as vestibular schwannoma
- • Patients with moderate to severe hepatic insufficiency
- • Patients with major depression disorder or suicide attempt
- • Patients with glaucoma
About Chang Gung Memorial Hospital
Chang Gung Memorial Hospital, one of the largest healthcare organizations in Taiwan, is renowned for its commitment to advancing medical research and improving patient care. As a clinical trial sponsor, the hospital leverages its extensive clinical expertise and state-of-the-art facilities to conduct innovative research across various medical disciplines. With a focus on collaboration and ethical practices, Chang Gung Memorial Hospital aims to contribute to the global body of medical knowledge through rigorous clinical trials that enhance treatment options and improve health outcomes for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New Taipei City, Taiwan
Patients applied
Trial Officials
BANG-YAN ZHANG, MD.
Study Chair
New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials